More than 100,000 people in the U.S. have become allergic to red meat since 2010 because of a weird syndrome triggered by tick bites, according to a government report released Thursday. But health officials believe many more have the problem and don't know it.
A second report estimated that as many as 450,000 Americans have developed the allergy. That would make it the 10th most common food allergy in the U.S., said Dr. Scott Commins, a University of North Carolina researcher who co-authored both papers published by the Centers for Disease Control and Prevention.
Health officials said they are not aware of any confirmed deaths, but people with the allergy have described it as bewildering and terrifying.
“I never connected it with any food because it was hours after eating,” said one patient, Bernadine Heller-Greenman.
The reaction, called alpha-gal syndrome, occurs when an infected person eats beef, pork, venison or other meat from mammals — or ingests milk, gelatin or other mammal products.
It’s not caused by a germ but by a sugar, alpha-gal, that is in meat from mammals — and in tick spit. When the sugar enters the body through the skin, it triggers an immune response and can lead to a severe allergic reaction.
Scientists had seen reactions in patients taking a cancer drug that was made in mouse cells containing the alpha-gal sugar. But in 2011 researchers first reported that it could spread through tick bites, too.
They tied it to the lone star tick, which despite its Texas-themed name is most common in the eastern and southern U.S. (About 4% of all U.S. cases have been in the eastern end of New York’s Long Island.)
One of the studies released Thursday examined 2017-2022 test results from the main U.S. commercial lab looking for alpha-gal antibodies. They noted the number of people testing positive rose from about 13,000 in 2017 to 19,000 in 2022.
Experts say cases may be up for a variety of reasons, including lone star ticks' expanding range, more people coming into contact with the ticks or more doctors learning about it and ordering tests for it.
But many doctors are not. The second study was a survey last year of 1,500 U.S. primary care doctors and health professionals. The survey found nearly half had never heard of alpha-gal syndrome, and only 5% said they felt very confident they could diagnose it. Researchers used that information to estimate the number of people with the allergy — 450,000.
People with the syndrome can experience symptoms including hives, nausea, vomiting, diarrhea, severe stomach pain, difficulty breathing, dizziness and swelling of the lips, throat, tongue or eye lids. Unlike some other food allergies, which occur soon after eating, these reactions hit hours later.
Some patients have only stomach symptoms, and the American Gastroenterological Association says people with unexplained diarrhea, nausea and abdominal pain should be tested for the syndrome.
Doctors counsel people with the allergy to change their diet, carry epinephrine and avoid tick bites.
The allergy can fade away in some people — Commins has seen that happen in about 15% to 20% of his patients. But a key is avoiding being re-bitten.
“The tick bites are central to this. They perpetuate the allergy,” he said.
One of his patients is Heller-Greenman, a 78-year-old New York art historian who spends summers on Martha's Vineyard. She has grown accustomed to getting bitten by ticks on the island and said she has had Lyme disease four times.
About five years ago, she started experiencing terrible, itchy hives on her back, torso and thighs in the middle of the night. Her doctors concluded it was an allergic reaction, but couldn't pinpoint the trigger.
She was never a big meat eater, but one day in January 2020 she had a hamburger and then a big, fatty steak the following evening. Six hours after dinner, she woke up nauseated, then suffered terrible spells of vomiting, diarrhea and dizziness. She passed out three times.
She was diagnosed with alpha-gal syndrome shortly after that, and was told to avoid ticks and to stop eating red meat and dairy products. There have been no allergic reactions since.
“I have one grandchild that watches me like a hawk," she said, making sure she reads packaged food labels and avoids foods that could trigger a reaction.
“I feel very lucky, really, that this has worked out for me," she said. “Not all doctors are knowledgeable about this.”
The FDA has granted emergency use authorization to Pfizer's pill to treat covid-19. The treatment, called Paxlovid, is the first antiviral covid-19 pill that people can take at home.
Pfizer says the pill can reduce the risk of severe illness by 90 percent and is intended for people at high risk for severe disease, including those over 65, people with obesity, diabetes, or a weakened immune system. Professor Peter Pitts, Founder, Center for Medicine in the Public Interest & Former FDA Associate joined Wake Up with Cheddar to discuss.
Ahead of a four day week for the markets due to the upcoming Christmas holiday, investors hoping for a quiet end to the year, or even a Santa Claus rally, may not be in luck. Investors are still digesting the latest from the Fed regarding a quicker than expected taper, as well as ever increasing blow back as the Omicron variant spreads. Octavio Marenzi, CEO of Opimas LLC, explains why the markets have been so volatile ever since the emergence of the latest variant and what to expect going forward into 2022.
Carlo and Baker cover the heartening news on the Covid front ahead of the holiday, plus President Biden punting student loan repayments again, a new space telescope and Love, Hate, Ate: Christmas Eve Eve Edition!
Pfizer, one of the makers of a currently available COVID-19 vaccine, has taken another critical step forward in combatting the pandemic by getting regulatory approval for Paxlovid, a pill treatment rather than IV or injection as others have been. Dr. Purvi Parikh, an immunologist with the Allergy and Asthma Network, spoke to Cheddar about the ramifications of the authorization. "This is huge, especially because we know early treatment does keep people out of the hospital, especially with this antiviral," Parikh said. "The fact that people can start a regimen at home so they don't have to leave and further expose others is a big breakthrough." She also explained how the drug is a combination of two antiviral medications that are not without its risks but should be safe over the short term.
This year's worldwide semiconductor shortage limited the supply of everything from new cars to smartphones; and now, many in the chip industry expect the shortage to continue deep into 2022, and maybe even 2023. Semiconductor senior research analyst for Robert W. Baird & Co., Tristan Gerra, joins Cheddar News' Closing Bell to discuss.
Direct health care company Nomi Health recently raised $110 million in a Series A round. Nomi Health lets public and private organizations directly purchase healthcare at reduced costs, and pay providers in real-time. It also delivers healthcare directly to under-served communities via its fleet of mobile care units, which the company says is the largest in the country. Nomi Health says its mission is to improve the health care experience for all Americans. Nomi Health CEO Mark Newman joined Cheddar News' Closing Bell to discuss.
The airline industry says it is contending with staff shortages that threaten to hamper operations amid the COVID resurgence, andDelta Airlines CEO Ed Bastian called on the CDC to revise its guidance for vaccinated workers who test positive from a 10-day quarantine to just five. Chuck Liberman, chief investment officer and managing partner at Advisors Capital Management LLC, joined Cheddar to talk about the current guidance on isolation and why he believes the omicron variant calls for more relaxed guidance given its reportedly mild symptoms.
The boys discuss President Biden's plans to send out free rapid tests as the testing supply chain starts to buckle ahead of the holidays. Also, why aren't Americans having more babies, and The Matrix returns.
NASA is launching its new generation of space telescopes just before Christmas. The James Webb Space Telescope, set to launch on December 24th, will succeed the Hubble space telescope as the world's most powerful complex space observatory. The project has been 30 years in the making and is one of the most highly anticipated space science missions of the 21st century. Klaus Pontoppidan, astronomer and JWST Project Scientist at the Space Telescope Science Institute joined Cheddar's Opening Bell to discuss.
With Omicron becoming the dominant COVID-19 variant in the U.S., President Joe Biden announced that he will make 500 million rapid tests available to Americans in January 2022. Cheddar News speaks with Dr. Shereef Elnahal, President and CEO of University Hospital why testing is key to combatting the spread of the virus.
